This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication Symptomatic treatment of seasonal allergic conjunctivitis.
Therapeutic Area (MeSH)
N/AATC Code
S01GX06
ATC Item
emedastine
Pharmacotherapeutic Group
Ophthalmologicals
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| emedastine difumarate | N/A | HP-30 |
EMA Name
Emadine
Medicine Name
Emadine
Aliases
N/ANo risk management plan link.